Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) wholly owned subsidiary, Rocket Doctor Inc., expanded in-network access to physician-led virtual care in New York through a new agreement entered into by doctors using its digital health platform and marketplace.
Under the agreement, Rocket Doctor is now accessible to more than 100,000 additional eligible lives across participating individual Medicare Advantage PPO and commercial health plans in the New York metropolitan region and select upstate counties.
The estimate excludes millions of members covered through administrative services only or self-insured plans. The payer also participates in a national reciprocal network program, allowing eligible out-of-state members to access Rocket Doctor's in-network physicians while traveling in New York.
With the latest agreement, Rocket Doctor has potential in-network access to approximately 10 million covered lives across New York and approximately 24 million covered lives across the United States through its network of commercial and public payer relationships.
The agreement was signed on July 15 and has an initial one-year term, with automatic one-year renewals unless terminated or non-renewed by either party in accordance with its terms.
Rocket Doctor's programs allow patients to connect with licensed physicians from home for services including urgent care, chronic disease management, preventive health, pediatrics, and mental health support. Eligible members can access the services through their existing insurance coverage under Rocket Doctor's in-network participation.
"This agreement represents another important milestone in our strategy to expand reimbursed access to physician-led care," said Dr. William Cherniak, co-founder and chief executive officer of Rocket Doctor. "By increasing the number of patients who can connect with physicians through their existing health benefits, we are helping reduce financial barriers to care while building a more sustainable model for delivering high-quality virtual care at scale."
Digital Health and AI Reshape Healthcare Delivery
The World Bank Group's Paschal Donohoe wrote on August 3 that healthcare systems globally had been facing pressure from aging populations, rising chronic disease, and growing demand for specialized care, while geography continued to affect access to timely care. He described digital technology as a way to extend healthcare services when it was "well-designed, governed responsibly, and embedded in broader health-system reform."
Donohoe pointed to virtual healthcare programs that had combined medical expertise with digital technologies to provide remote services, including virtual critical care, specialty consultations, and home-care services. He wrote that "digital technology can improve patient care" by extending expertise beyond hospital walls.
At the same time, Donohoe cautioned that technology was not a substitute for the broader healthcare system. "Virtual care is not a shortcut to deeper healthcare reforms," he wrote. "It cannot replace skilled providers, systems, or patient trust." He said digital healthcare raised legal and regulatory questions and that countries needed to determine which services were clinically effective and which training approaches best helped workers serve patients.
A report distributed through EIN Presswire on August 10 said U.S. healthcare and pharmaceutical marketers were expected to spend US$26.15 billion on digital advertising during 2026, representing a 5.6% year-over-year increase, according to eMarketer. The report also said 2025 marked the first year that social media spending exceeded linear television spending in the category.
The report described physician access as having become increasingly difficult as in-person access tightened and marketers shifted toward scalable digital channels. It cited industry benchmarks indicating that B2B email lists decayed at roughly 22.5% annually and said physician data could decay more quickly as doctors changed hospitals, completed residencies, and moved among healthcare systems.
Digital strategist Harsh Nigam described the consequences of inaccurate physician data in the report. "The real cost of bad data isn't the bounce, it's the physician, a competitor reached while your email went nowhere," Nigam said. "In healthcare, missed inboxes are missed prescribers."
The report also identified fragmentation as an issue in healthcare marketing, with data, email, search, and content sometimes handled separately. Harjyot Singh Isser said effective digital engagement required those functions to work together. "A verified physician database only pays off when the email, the content, the search visibility, and the targeting all move together," Isser said.
In an August 11 article, Gilda D'Incerti examined healthcare AI adoption through the industry's previous experiences with electronic health records, revenue-cycle modernization, telehealth expansion, and other digital transformations. She wrote that healthcare's experience had shown that technological implementation depended on organizational factors, including workflow redesign, clinician acceptance, and training.
D'Incerti said AI initiatives had encountered similar considerations as healthcare organizations evaluated platforms, governance, and regulatory compliance. "The bigger challenge is helping people understand how AI fits within daily work, building trust, and integrating it into workflows," she wrote. "In other words, the challenge is not simply technological. It is organizational."
She also emphasized clinician participation in technology adoption, noting that healthcare professionals had expressed concerns involving transparency, reliability, accountability, and workflow effects. "Adoption cannot be mandated. It must be earned," D'Incerti wrote.
Workflow integration was another factor identified in the article. D'Incerti wrote that healthcare organizations had previously found that technology by itself did not improve outcomes and that benefits emerged when technology corresponded with clinical workflows. "The most successful AI deployments are those that integrate into existing environments, support decision-making, and eliminate administrative burden instead of adding complexity," she wrote.
Trust also remained an important consideration because healthcare technology affected care outcomes, regulatory compliance, and organizational performance. D'Incerti said clinicians and staff expected transparency about how technologies functioned and how recommendations were generated. She concluded that healthcare's earlier digital transformations had demonstrated the importance of clinician engagement, workflow alignment, leadership commitment, workforce readiness, and organizational trust.
Technical Analyst Rated Rocket Doctor AI a Strong Speculative Buy
Thomson described Rocket Doctor's technology as being developed around the needs of healthcare providers. He wrote that the company's AI platform "is designed by doctors, so doctors who use it get exactly what they need," and said its approach was "centered on enhancing provider capabilities, not replacing clinical decisions." He also cited smart triage and matching technology, remote patient monitoring, multilingual care, and support for multiple medical specialties.
The analyst also discussed Rocket Doctor's expansion in the United States. He cited an in-network agreement in New York that he said increased the company's nationwide reach to more than 15 million members. Thomson also referenced a US$1 million Healthy Aging Program grant launched with CVS Health Foundation, through a partnership the Company announced with Engagewell on July 10, 2025.
Addressing the company's U.S. operations, Thomson cited its technology, payer contracts, physician credentialing, and revenue operations. He wrote that competitors faced "a minimum of 18 to 24+ months to replicate the position Rocket Doctor AI is in today."
Thomson established three technical price targets for the shares: CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 in the long term.
Payer Expansion, Physician Credentialing, and AI Development Remain on the Agenda
The presentation identified Florida and Texas among the company's state expansion pipeline and listed its strategy as extending existing relationships with payers. At the time reflected in the presentation, Rocket Doctor listed 9,875,993 covered lives with potential in-network access in New York, 8,126,637 in California, and 3,180,599 in Maryland.
The company's U.S. payer approach covers channels including: Medicaid and Medicaid Managed Care, Medicare and Medicare Advantage, HR and employer benefits, and commercial insurance, and out-of-network patients. The presentation stated that each payer relationship could provide indicative potential access to 1 million to 2 million or more covered lives.
Physician credentialing represents another ongoing work stream. The presentation reported 22 clinically active U.S. physicians and another 33 physicians in credentialing. It also listed pending physician capacity at three times the number of clinically active U.S. physicians.
Rocket Doctor AI also described a connected suite of healthcare AI solutions encompassing its digital health platform and marketplace, AI Assistants, Electronic Medical Records (EMR), access to Bluetooth-enabled medical devices, AI Scribe, the Global Library of Medicine (GLM), and billing and revenue reconciliation.
The company's AI-supported care workflow covers intake, patient visits, and follow-up. Intake features listed in the presentation include symptom-based smart intake, doctor and patient matching, auto-booking, initial care assessments, and an AI agent. Patient-visit functions include AI-driven diagnostic support, questioning through chat and video, appointments, referrals, labs and imaging, and real-time updates to the patient chart. Follow-up functions include chronic-condition management, future appointments and reminders, preset follow-ups, and an AI agent.
Rocket Doctor AI's Global Library of Medicine (GLM) has been in development since 2016, with more than 25,000 hours of input from hundreds of clinicians globally and approximately 10,000 or more expert medical reviews. The GLM includes more than 1,000 diseases and 17,000 symptoms in real time and suggests appropriate lab tests and imaging, treatment options, and billing codes. The company also described plug-and-play API integration for connecting the system to other platforms, such as EMR’s, AI Scribes, and or other healthcare systems offering patient-facing services.
The presentation also identifies continued physician and patient activity and growth in the United States. Total completed U.S. patient visits increased from 86 in December 2025 to 177 in January, 464 in February, 678 in March, and 1,144 in April. U.S. clinical hours increased from 75 in December to 110 in January, 434 in February, 577 in March, and 624 in April.
Streetwise Ownership Overview*
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 08/21/25 | TRUE:OTC | 1 | AIDR:OTC | 1 |
| 11/09/23 | TREID:CSE | 10 | TREIF:CSE | 1 |
| 07/14/23 | TRUE:OTC | 10 | TRUE:OTC | 1 |
| 07/14/23 | TREIF:CSE | 1 | TREID:CSE | 1 |
Ownership and Share Structure2
As of August 13, 2026, Insider ownership of Rocket Doctor AI totals 4.24%. Retail investors hold the rest.
As of August 13, 2026, Rocket Doctor AI has approximately 101.03 million shares outstanding. Its market capitalization is approximately CA$59.61 million, and its 52-week trading range is CA$0.47 to CA$0.98 per share.
Frequently Asked Questions About Rocket Doctor AI
What is Rocket Doctor AI Inc.?
Rocket Doctor AI Inc. provides a suite of healthcare technology. Through its wholly owned subsidiary, Rocket Doctor Inc., its operations include a digital health platform and marketplace, virtual physician care, and healthcare AI tools designed to support providers across the care process.
What did Rocket Doctor AI announce about its access to New York healthcare network?
Rocket Doctor announced an agreement expanding potential in-network access to physician-led virtual care for a further 100,000+ additional eligible covered lives across participating individual Medicare Advantage PPO and commercial health plans in the New York metropolitan region and select upstate counties.
How many covered lives does Rocket Doctor have access to in New York and the United States?
Following the latest agreement, Rocket Doctor said it has potential in-network access to approximately 10 million covered lives across New York and approximately 24 million covered lives across the United States through its network of commercial and public payer relationships.
When did Rocket Doctor sign its latest New York health plan agreement?
The agreement was signed on July 15. It has an initial one-year term and automatically renews for additional one-year periods unless either party terminates or does not renew it in accordance with the agreement's terms.
What healthcare services does Rocket Doctor provide through its virtual care platform?
Rocket Doctor's programs connect patients with licensed physicians from home for services that include urgent care, chronic disease management, preventive health, pediatrics, and mental health support.
Can patients use health insurance to access Rocket Doctor physicians?
Eligible members covered by participating health plans can access Rocket Doctor's in-network physician services through their existing insurance coverage. There is also scope for private pay.
Can out-of-state patients access Rocket Doctor physicians while visiting New York?
The payer involved in Rocket Doctor's latest agreement participates in a national reciprocal network program. This facilitates eligible out-of-state members to access Rocket Doctor's in-network physicians while traveling in New York.
How is Rocket Doctor AI using artificial intelligence in healthcare?
Rocket Doctor AI is using AI in the development of its solutions, and in particular, healthcare technology includes AI-assisted intake, AI-driven diagnostic support, smart triage, doctor and patient matching, an AI Assistant, AI Scribe, and AI-supported follow-up functions. Its platform also includes the Global Library of Medicine. It’s important to note that all of the technology is validated through physician groups for accuracy before being released.
What is Rocket Doctor AI's Global Library of Medicine?
The Global Library of Medicine, or GLM, has been developed since 2016 with more than 25,000 hours of input from hundreds of clinicians globally and approximately 10,000 or more expert medical reviews. According to the company's investor overview, it covers more than 1,000 diseases and 17,000 symptoms in real time and can suggest appropriate lab tests and imaging, treatment options, and billing codes.
How many physicians are active or credentialed with Rocket Doctor in the United States?
Rocket Doctor AI's August investor overview reported 22 clinically active U.S. physicians and another 33 physicians undergoing credentialing.
How many U.S. patient visits has Rocket Doctor reported?
The company's investor overview showed completed U.S. patient visits increasing from 86 in December 2025 to 177 in January, 464 in February, 678 in March, and 1,144 in April.
What U.S. health insurance markets is Rocket Doctor targeting?
Rocket Doctor AI's investor overview identified four primary channels in its U.S. payer approach: Medicaid and Medicaid Managed Care, Medicare and Medicare Advantage, HR and employer benefits, and commercial insurance, and out-of-network care.
Where is Rocket Doctor planning additional U.S. healthcare expansion?
The company's August investor overview identified Florida and Texas among its state expansion pipeline and listed extending existing relationships with payers as its strategy.
What rating did technical analyst Stewart Thomson give Rocket Doctor AI stock?
In a March 17 report, technical analyst Stewart Thomson assigned Rocket Doctor AI a Strong Speculative Buy technical rating.
What were Stewart Thomson's price targets for Rocket Doctor AI stock?
Thomson set technical price targets of CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 in the long term.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals and Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Rocket Doctor is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1 Disclosure for the quote from the Stewart Thomson article published on March 17, 2026
- For the quoted article (published on March 17, Rocket Doctor has paid Street Smart, an affiliate of Streetwise Reports, US$2,500
- Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
2. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
